Abstract
Following Brexit, the MHRA has become the standalone regulator for medicines in the UK (except Northern Ireland). To ensure timely access to innovative oncology products, the UK joined Project Orbis, an FDA-led review programme. This research compares UK reimbursement outcomes for medicines approved through Project Orbis with EU4.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
